retatrutide mechanism triple agonist glp-1 gip glucagon receptor just had its biggest data year yet. In 2026, Eli Lilly's GLP-1/GIP/glucagon posted two major Phase 3 readouts: TRIUMPH-1 (obesity, 2,339 participants) showed a 28.3% average body weight Simple Peptide retatrutide: complete guide

Additionally in February, the FDA has sent Wegovys maker, Novo Nordisk, a letter indicating that one of its TV advertisements is false or misleading

Semaglutide, tirzepatide, and high dose dulaglutide have been deemed to have very high likelihood of achieving adequate blood sugar control, while other GLP-1s have been deemed highly likely

2023 Sep 7;389(10):877-888

It syncs medication schedule with biometric feedback, translating injections into insights

Administration Routes and Techniques Most GLP-1 agonists are administered via subcutaneous injection, meaning the medication is injected into the fatty tissue just under the skin

GLP-1 side effects All of the GLP-1s went through an extensive clinical review and approval process and are considered generally safe medications